Evidence map›Paper›PMID 40741703›Full record

ArticleJournal of managed care & specialty pharmacy2025

A structured approach for identifying disease analogs for pulmonary arterial hypertension.

Karim El-Kersh, Nadine Zawadzki, Anna Watzker, Shurui Zhang, Dhruv Dalal, Dominik Lautsch, Jason Shafrin

Abstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karim El-KershUniversity of Arizona College of Medicine, Phoenix.
Nadine ZawadzkiFTI Consulting, Los Angeles, CA.
Anna WatzkerMerck & Co., Inc., Rahway, NJ.
Shurui ZhangFTI Consulting, Washington, DC.
Dhruv DalalFTI Consulting, Washington, DC.
Dominik LautschMerck & Co., Inc., Rahway, NJ.
Jason ShafrinFTI Consulting, Los Angeles, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug manufacturers often use disease analogs to describe diseases-particularly rare diseases-to payers, policymakers, and stakeholders. However, these comparisons are typically anecdotal. We propose a 4-step, systematic approach to identify disease analogs based on prespecified metrics and apply it to a rare disease, pulmonary arterial hypertension (PAH), as a case study. When there is limited knowledge of a rare disease, such as PAH, the application of the systematic disease analog approach presented can help managed care pharmacists leverage their existing knowledge and perspectives applied to other conditions to inform coverage, tier placement, and pricing decisions.

Indexed as

Antihypertensive AgentsHypertension, PulmonaryPulmonary Arterial HypertensionRare DiseasesHumansManaged Care ProgramsAntihypertensive Agents

Identifiers

PMID40741703
PMCPMC12397978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.